Why Axsome Therapeutics Inc (AXSM) Stock Is Rising
As of 2026-07-31, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 336.82%. Featured in our EPS revision report on 2026-05-04.
Why AXSM Stock Is Rising
- +EPS Estimate Upgraded: Analysts raised Axsome Therapeutics Inc's next-year EPS growth estimate from 327.46% to 328.63% on 2026-07-28.
- →Estimate Trending Higher: Since detection, the estimate has moved up a net +8.19 pp to 336.82% across 1 upward revision.
- !Largest Single-Day Revision: +8.32 pp on 2026-07-31 (328.50% → 336.82%).
- ·Current-Year Growth: Projected at 37.58%, supporting the forward estimate revision.
News Context
The primary structural driver is the upward revision to next-year EPS growth estimates, which have continued climbing to 336.82% since the
Generated 2026-07-31 · news as of 2026-07-31
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 336.82%
- EPS growth this year
- 37.58%
- EPS next quarter (est)
- -$0.89
- Last price
- $217.99
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-07-31 | 336.82% | 37.58% | -$0.89 | $217.99 |
| 2026-07-30 | 328.50% | 38.01% | -$0.89 | $234.64 |
| 2026-07-29 | 328.63% | 37.49% | -$0.89 | $227.42 |
| 2026-07-28 | 328.63% | 37.49% | -$0.89 | $234.20 |
| 2026-07-27 | 327.46% | 37.29% | -$0.89 | $238.37 |
| 2026-07-26 | 327.46% | 37.29% | -$0.89 | $241.00 |
| 2026-07-24 | 327.46% | 37.29% | -$0.89 | $241.00 |
| 2026-07-23 | 327.46% | 37.29% | -$0.89 | $241.53 |
| 2026-07-22 | 327.46% | 37.29% | -$0.89 | $239.62 |
| 2026-07-21 | 327.46% | 37.29% | -$0.89 | $236.95 |
| 2026-07-20 | 325.32% | 36.34% | -$0.90 | $221.64 |
| 2026-07-19 | 327.31% | 36.89% | -$0.89 | $230.00 |
| 2026-07-17 | 345.99% | 40.54% | -$0.85 | $230.00 |
| 2026-07-16 | 345.99% | 40.54% | -$0.85 | $237.04 |
| 2026-07-15 | 345.99% | 40.54% | -$0.85 | $237.53 |
| 2026-07-14 | 345.99% | 40.54% | -$0.85 | $235.26 |
| 2026-07-13 | 345.99% | 40.54% | -$0.85 | $228.28 |
| 2026-07-12 | 353.29% | 40.81% | -$0.86 | $233.80 |
| 2026-07-09 | 360.80% | 42.51% | -$0.85 | $248.95 |
| 2026-07-08 | 360.80% | 42.51% | -$0.85 | $245.57 |
| 2026-07-07 | 360.80% | 42.51% | -$0.85 | $249.76 |
| 2026-07-06 | 357.30% | 41.91% | -$0.85 | $242.60 |
| 2026-07-05 | 357.30% | 41.91% | -$0.85 | $244.31 |
| 2026-07-02 | 357.30% | 41.91% | -$0.85 | $244.31 |
| 2026-07-01 | 357.28% | 41.90% | -$0.85 | $240.66 |
| 2026-06-30 | 357.28% | 41.90% | -$0.85 | $244.77 |
| 2026-06-29 | 357.30% | 41.91% | -$0.85 | $241.12 |
| 2026-06-28 | 373.96% | 45.44% | -$0.85 | $241.67 |
| 2026-06-25 | 373.96% | 45.44% | -$0.85 | $237.33 |
| 2026-06-24 | 373.96% | 45.44% | -$0.85 | $237.92 |
Reports Featuring AXSM
Recent News
- Shopify downgraded, Five Below upgraded: Wall Street's top analyst callsThe Fly
- Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)GlobeNewswire
- TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits
- TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay SchemeStocktwits
- Axsome Therapeutics, Inc. Q1 2026 Earnings Call SummaryMoby
- Axsome: Q1 Earnings SnapshotAssociated Press
- Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business UpdateGlobeNewswire
- Summits self-inflicted stumble; Esperions take-private dealBioPharma Dive
- Summits self-inflicted stumble; Esperions take-private dealBioPharma Dive
- Axsome Therapeutics Hosts AUVELITY FDA Approval Investor Event Featuring Expert Thought LeaderGlobeNewswire
Screen Performance
Aggregate stats across all 1903 tickers our top-EPS-revision screen has flagged over the past 121 days.
- Median return since detection
- +1.2%
- % of tickers in the green
- 52%
- Median return on winners
- +18.8%
- Large revisions captured
- 1198
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
Why did Axsome Therapeutics Inc (AXSM) stock go up recently?▾
Axsome Therapeutics Inc (AXSM) stock has risen following an analyst upgrade of its next-year EPS growth estimate from 327.46% to 328.63% on 2026-07-28. Since detection, the estimate has moved up a net +8.19 pp to 336.82%. EPS estimate upgrades are among the strongest leading indicators of stock outperformance.
What is Axsome Therapeutics Inc's next-year EPS growth estimate?▾
As of 2026-07-31, Axsome Therapeutics Inc (AXSM) has a next-year EPS growth estimate of 336.82%, based on analyst consensus.
When was the latest EPS estimate revision for AXSM?▾
The most recent revision occurred on 2026-07-31, when analysts adjusted the next-year EPS growth estimate from 328.50% to 336.82%.
What sector and industry does Axsome Therapeutics Inc belong to?▾
Axsome Therapeutics Inc operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. AXSM appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Axsome Therapeutics Inc (AXSM) appears here because it was detected by our daily top-EPS-revision-performer screen.